Apixaban to Prevent Venous Thromboembolism in Patients with Cancer

Short summary

Apixaban (2.5 mg twice daily) significantly reduced venous thromboembolism (VTE) by 58% in ambulatory cancer patients at intermediate-to-high risk starting chemotherapy, compared to placebo (4.2% vs. 10.2%). However, it also doubled the rate of major bleeding events (3.5% vs. 1.8%).

AI-generated from the title and abstract; the full text is not read.